Could This Humira Biosimilar Be a Winner for Amgen?

• Amgen’s biosimilar called Amjevita could provide cost savings to countless patients.
• Amjevita could generate $900 million in annual revenue for the drugmaker.
• The stock is a no-brainer buy for dividend growth investors.

Amgen’s biosimilar called Amjevita could provide cost savings to countless patients.Amjevita could generate $900 million in annual revenue for the drugmaker.The stock is a no-brainer buy for dividend growth investors.